Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LN-145 in Metastatic Non-Small-Cell Lung Cancer
NCT04614103Phase 2Recruiting
- Sponsor
- Iovance Biotherapeutics
- Start
- May 2021
- Primary completion
- Dec 2030
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 12
01
Overview
Phase 2, open-label trial of LN-145 in non-small cell lung cancer (NSCLC) (5 cohorts), sponsored by Iovance Biotherapeutics. Primary endpoint: Objective Response Rate at 60 months. Started May 2021; status: recruiting.
02
Drugs
LN-145
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04614103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614103.